As well, screening inhibitors of TOP2A overexpressed in ACC, which regulates cellular proliferation and invasion in ACC cells, has successfully been used to identify aclarubicin, a good drug candidate for clinical trials in patients with locally advanced and metastatic ACC [82]. This evidence concerns the gene TOP2A and adrenal cortex carcinoma.